First EFIC® Symposium Societal Impact of Pain - SIP

More documents

Recommendations

Info

54 Magdi Hanna Magdi Hanna MD Director of Analgesics & Pain Research Unit (APRU) APRU PO BOX 22 BECKENHAM KENT, BR3 1UR ENGLAND, UK TEL/ FAX:00442083256473 MOBILE:0044778525560 EMAIL:MAGDIHANNA6262@AOL.COM Magdi H. Hanna became Director of the Pain Research Unit (PRU) at King’s College School of Medicine in London (UK) in 1985. Since then he has been an Honorary Senior Lecturer at King’s College School of Medicine and Dentistry, Director of the Pain Relief Unit and Consultant in Pain Medicine at the Department of Anaesthesia, Intensive Care and Pain Relief at King’s College Hospital, London. He became the Clinical Director of PCRH (Pain Clinical Research Hub), a collaborative academic research unit at King’s College School of Medicine and Pfizer in 2003 that specializes in developing pain biomarkers for chronic, nociceptive and neuropathic pain states. He has been Member of the European Academy of Anesthesiology, European Association for Palliative Care (EAPC), International Association of the Study of Pain (IASP) and the British Pain Society for the last 25 years. He has published extensively on the subject of pain, and has been an invited speaker in numerous pain and anesthesiology meetings, both nationally and internationally. Currently a Consultant in Pain Medicine in the Independent Health sector and the Clinical Director of the “Analgesics &Pain Research Unit” (APRU) which acts as an independent advisory unit for the pharmaceutical industry and research units on drug development, use of human pain models, translational research and Phase II clinical studies as well as conducting due clinical diligent and registration filing advice. He is a member of “Pain Medicine Teachers” group and is on the Faculty of the 1st EFIC school for “NEUROLOGICAL DIAGNOSIS IN CHRONIC PAIN”. The Social Costs of Painful Diabetic Neuropathy The dramatic increase in newly diagnosed cases of type 2 diabetes is a major public health concern within the European Union. It has been estimated that up to 50% of people with type 2 diabetes will develop a degree of neuropathy (Boulton, 2005). At least 20% of those affected are likely to suffer from chronic neuropathic pain. The majority of PDN patients experienced constant moderate to very severe pain. In addition to the pain itself, there are associated high levels of co-morbidity and related symptoms, including difficulty sleeping, depression, and anxiety. This has led to significant impairments in quality of life (Benbow et al, 1998; Galer et al, 2000). PDN is a clear area of unmet clinical needs. Currently there is no effective therapy to treat, prevent or reverse the neuropathy once it has been established. The goals of available therapies are: pain, symptom control, a reduction of co-morbidity and an improvement in quality of life. Traditionally antidepressants, anticonvulsants, and opioids have been the main compounds used for pain control in PDN patients. Newer agents, such as SNRI (eg duloxatine), α2δ ligands (gabapentin, pregabalin) have been found to have proven efficacy in treating PDN. However, all of these compounds have less than 50% responder rate and most patients are left with significant residual pain. Adverse side effects are a considerable hurdle for patients, particularly sedation and weight gain. Overall the quality of PDN treatment appears to be poor, with few patients receiving recommended medications in efficacious dosages. Though knowledge of the health care costs associated with neuropathic pain is somewhat limited, recent studies have identified that PDN has the highest additional health care costs even in comparison with other painful neuropathies such as postherpetic neuralgia (PHN) (Dworkin RH 2009). The substantial cost to society of PDN derives from direct medical costs, loss of the ability to work, loss of caregivers' ability to work and possibly greater need for institutionalization or other living assistance (O’Connor AB 2009 ). The cost of managing painful diabetic neuropathy can increase the basic cost of managing diabetes by two and up to 10 fold depending on the degree of associated co-morbidity such as anxiety and depression (Boulanger L 2009). It is hoped that better understanding of the economic burden of PDN will provide a basis for evaluating the impact on health care costs of new interventions for their treatment and prevention.
Per Hansson Prof. Per Hansson, MD, DMSc, DDS Professor of Clinical Pain Research Department of Molecular Medicine and Surgery Karolinska Institutet, Stockholm & Senior Consultant and Section Head, Pain Center Department of Anaesthesiology and Intensive Care Karolinska University Hospital (Solna) Stockholm Sweden Per Hansson is professor of clinical pain research at Karolinska Institutet and a specialist in neurology and pain medicine at the Karolinska University Hospital in Stockholm, Sweden. Professor Hansson is head of and a senior consultant at the Pain Center, Department of Anaesthesiology and Intensive Care, and head of Clinical Pain Research, Department of Molecular Medicine and Surgery at Karolinska Institutet. He received his dental and medical degrees from the Karolinska Institute in 1979 and 1986, respectively, and his PhD in physiology at the same institute in 1985. He was appointed associate professor of physiology in 1991 and professor of clinical pain research in 2000. Peripheral and central neuropathic pain, somato-sensory testing, endogenous pain controlling systems and functional brain imaging represent major areas of interest in Professor Hansson’s research. Professor Hansson is a reviewer for many scientific journals and has served as co-editor of Pain Reviews, on the editorial board of Pain, Clinical Updates and is currently field editor for clinical medicine/neurology of the European Journal of Pain. He has published close to 150 journal articles and book chapters, and has lectured at numerous conferences and symposia worldwide. He is co-editor of 2 books published by the IASP Press. Per Hansson is a member of several professional societies such as the International Association for the Study of Pain and has served as scientific secretary of the Swedish Society of Algology and as scientific advisor to the Swedish Medical Product Agency. From 2003- 2006 he was president of the Scandinavian Association for the Study of Pain. He is currently Honorary Secretary of the European Federation of IASP Chapters. 55
Page 1 and 2:
SIP Societal Impact of Pain First E
Page 3: SIP Societal Impact of Pain First E
Page 6 and 7: 6 ABOUT EFIC ® The European Federa
Page 8 and 9: 8 General Information All speakers
Page 10 and 11: 10 Floor plan CONFERENCE CENTRE/MEE
Page 12 and 13: 12 Draft program - May 4th 2010 Aud
Page 14 and 15: 14 Draft program - May 5th 2010 Par
Page 20 and 21: 20 Workshop 1 Prevalence & epidemio
Page 22 and 23: 22 SIP Societal Impact of Pain Firs
Page 24 and 25: 24 Emília Altarriba Alberch Emíli
Page 26 and 27: 26 Giovanni Apolone Giovanni Apolon
Page 28 and 29: 28 Mary Baker Mary G Baker, MBE Pre
Page 30 and 31: 30 Meindert Boysen Meindert Boysen
Page 32 and 33: 32 Ana Casas Dr. Ana Casas MD, PhD
Page 34 and 35: 34 Jose M. Castro Lopes Prof. José
Page 36 and 37: 36 Günter Danner Günter Danner M.
Page 38 and 39: 38 Jan Dobrogowski Prof. Jan Dobrog
Page 40 and 41: 40 Benjamin Ellis Dr. Benjamin Elli
Page 42 and 43: 42 Cornelius Erbe Dr. Cornelius Erb
Page 44 and 45: 44 Norman Evans Norman Evans Consul
Page 46 and 47: 46 Prof. Guido Fanelli MD Guido Fan
Page 48 and 49: 48 Livio Garattini Dr. Livio Garatt
Page 50 and 51: 50 Pietro Giusti Prof. Pietro Giust
Page 52 and 53: 52 Ewald Gspurning, MPH Ewald Gspur
Page 56 and 57: 56 Yves Henrotin Prof. Yves Henroti
Page 58 and 59: 58 Morten Hjulsager Prof. Morten Hj
Page 60 and 61: 60 Eric X. Jensen Dr. med Eric X. J
Page 62 and 63: 62 Paul Kind Prof. Paul Kind Centre
Page 64 and 65: 64 Harry Kletzko Vizepräsident Deu
Page 66 and 67: 66 Norbert Klusen Prof. Dr. Norbert
Page 68 and 69: 68 Marja R. Kuijpers Marja R. Kuijp
Page 70 and 71: 70 Pete Mackenzie Dr. Pete Mackenzi
Page 72 and 73: 72 Barbara Milani Barbara Milani Te
Page 74 and 75: 74 Laurette Onkelinx Laurette A.J.
Page 76 and 77: 76 Matthias Perleth PD Dr. med. Mat
Page 78 and 79: 78 Gina Plunkett Vice Chairperson,
Page 80 and 81: 80 Narinder Rawal Prof. Narinder Ra
Page 82 and 83: 82 Lise Rochaix Prof. Lise Rochaix
Page 84 and 85: 84 Ian Semmons Ian Semmons Chairman
Page 86 and 87: 86 Antoni Sicras Mainar Dr. Antoni
Page 88 and 89: 88 Reinhard Thoma Dr. med. Reinhard
Page 90 and 91: 90 Thomas R. Tölle Prof. Dr. med.
Page 92 and 93: 92 Martin van der Graaff Dr. Martin
Page 94 and 95: 94 Giustino Varrassi Prof. Giustino
Page 96 and 97: 96 Renata Villoro Renata Villoro Ph
Page 98 and 99: 98 Eva Zebedin-Brandl Dr. Eva Zebed
Page 100 and 101: 100 NOTES
Page 102 and 103: 102 NOTES
Page 104 and 105:
104 NOTES
Page 106 and 107:
106 NOTES
Page 108 and 109:
108 NOTES
Page 110 and 111:
NOTES 110 110
show all

First EFIC® Symposium Societal Impact of Pain - SIP

You also want an ePaper? Increase the reach of your titles

Delete template?

Save as template?